PARP7: an Emerging Therapeutic Target-Insights into Biological Functions and Advances in Small-Molecule Inhibitor Development
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c01335 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Feihuang Qiu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Poly(ADP-ribose) Polymerases, Small Molecule Libraries. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 144 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China, Jiangsu Funding Program for Excellent Postdoctoral Talent.
Abstract (Originalsprache)
PARP7 is a critically important member of the PARP family. Current research indicates that PARP7 is associated with various diseases, including viral infections, cancers, and stroke. Consequently, pharmacological modulation of PARP7 enzymatic activity has emerged as a crucial strategy for treating numerous diseases. Notably, the selective PARP7 inhibitor RBN-2397 for tumor treatment has entered Phase II trials, highlighting the translational potential of targeting this enzyme. This perspective summarizes the biological functions of PARP7 and its roles in various diseases. Furthermore, to advance the study of PARP7 inhibitors, we analyze the mechanisms of action and design strategies of existing PARP7 inhibitors as reported in current papers and patents. Additionally, we share our experiences in designing PARP7 inhibitors and present our insights regarding the opportunities and challenges in this pioneering research field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China.
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
ORCID-Profile: Yungen Xu, Hongfeng Gu
Förderung
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Jiangsu Funding Program for Excellent Postdoctoral Talent
Zitieren
APA
Qiu, F., Wang, J., Huang, K., Shang, T., Wang, C., Yan, W., Xu, Y., & Gu, H. (2025). PARP7: an Emerging Therapeutic Target-Insights into Biological Functions and Advances in Small-Molecule Inhibitor Development. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01335
Vancouver
Qiu F, Wang J, Huang K, Shang T, Wang C, Yan W, et al. PARP7: an Emerging Therapeutic Target-Insights into Biological Functions and Advances in Small-Molecule Inhibitor Development. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01335
BibTeX
@article{Qiu2025,
author = {Qiu, Feihuang and Wang, Jianqiao and Huang, Kehan and Shang, Tianxiang and Wang, Chenghao and Yan, Wenxin and Xu, Yungen and Gu, Hongfeng},
title = {PARP7: an Emerging Therapeutic Target-Insights into Biological Functions and Advances in Small-Molecule Inhibitor Development},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c01335}
}
EUVIMED